Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: Annexin A5 recombinant - Alavita; ASP-8597; Diannexin

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Alavita Pharmaceuticals
  • Developer Astellas Pharma
  • Class Anti-inflammatories; Anti-ischaemics; Anticoagulants; Antithrombotics; Biological peptides; Calcium binding proteins; Eye disorder therapies; Recombinant fusion proteins
  • Mechanism of Action Immunomodulators; Phosphatidylserine receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Reperfusion injury

Most Recent Events

  • 01 Jul 2013 Astellas Pharma terminates phase II/III trial in Reperfusion injury in USA (NCT01442337)
  • 04 Feb 2013 Discontinued - Phase-II/III for Reperfusion injury in USA (IV)
  • 26 Oct 2012 Astellas Pharma suspends a phase II/III trial in Reperfusion injury (prevention) in USA (NCT01442337)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top